Enhanced passive surveillance of influenza vaccination in England, 2016−2017– an observational study using an adverse events reporting card

Autor: De Lusignan, S, Ferreira, F, Damaso, S, Byford, R, Pathirannehelage, S, Yeakey, A, Yonova, I, Schuind, A, Dos Santos, G
Rok vydání: 2019
Předmět:
Adult
Male
medicine.medical_specialty
Adolescent
Influenza vaccine
030231 tropical medicine
Immunology
Pharmacovigilance
Young Adult
03 medical and health sciences
0302 clinical medicine
influenza
human
Environmental health
influenza vaccines
Adverse Drug Reaction Reporting Systems
Electronic Health Records
Humans
Immunology and Allergy
Medicine
030212 general & internal medicine
Child
Adverse effect
Aged
Aged
80 and over
Pharmacology
medical record systems
computerized
[MeSH]: General practice
business.industry
Data Collection
Incidence
Public health
Vaccination
Infant
Newborn
Infant
virus diseases
Middle Aged
Vaccines
Inactivated
Child
Preschool
drug-related side effects and adverse reactions
records as topic
adverse effects
Epidemiological surveillance
Female
Observational study
business
Records as Topic
Research Paper
Zdroj: Human Vaccines & Immunotherapeutics
ISSN: 2164-554X
2164-5515
DOI: 10.1080/21645515.2019.1565258
Popis: Influenza is a major public health burden, mainly prevented by vaccination. Recommendations on influenza vaccine composition are updated annually and constant benefit-risk monitoring is therefore needed. We conducted near-real-time enhanced passive surveillance (EPS) for the influenza vaccine, Fluarix Tetra, according to European Medicines Agency guidance, in 10 volunteer general practices in England using Fluarix Tetra as their principal influenza vaccine brand, from 1-Sep to 30-Nov-2016. The EPS method used a combination of routinely collected data from electronic health records (EHR) and a customized adverse events reporting card (AERC) distributed to participants vaccinated with Fluarix Tetra. For participants vaccinated with a different influenza vaccine, data were derived exclusively from the EHR. We reported weekly and cumulative incidence of pre-defined adverse events of interest (AEI) occurring within 7 days post-vaccination, adjusted for clustering effect. Of the 97,754 eligible participants, 19,334 (19.8%) received influenza vaccination, of whom 13,861 (71.7%) received Fluarix Tetra. A total of 1,049 participants receiving Fluarix Tetra reported AEIs; 703 (67%) used the AERC (adjusted cumulative incidence rate 4.96% [95% CI: 3.92−6.25]). Analysis by individual pre-specified AEI categories identified no safety signal for Fluarix Tetra. A total of 62 individuals reported an AEI with a known brand of non-GSK influenza vaccine and 54 with an unknown brand (adjusted cumulative incidence rate 2.59% [1.93−3.47] and 1.77% [1.42−2.20], respectively). In conclusion, the study identified no safety signal for Fluarix Tetra and showed that the AERC was a useful tool that complemented routine pharmacovigilance by allowing more comprehensive capture of AEIs.10.1080/21645515.2019.1565258-UF0001
Databáze: OpenAIRE
Externí odkaz: